Grifols SA (GRF)-Financial and Strategic SWOT Analysis Review

Region:Europe

Author(s):

Product Code:GDPH7524FSA

Download Sample Report download
Buy the Full ReportStarting from $125
Published on

April 2017

Total pages

71

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $125

About the Report

About the Report

Grifols SA (GRF)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Grifols SA (Grifols) focuses at improving the health and well-being of people around the world. It carries out the research, development, manufacturing and marketing of plasma-derived therapies, hospital pharmacy products and diagnostic technology for clinical use. The company specializes in the production of plasma-derived medicines and has plasma donation centers across the US. Grifols provides a wide range of transfusion medicine, hemostasis and immunoassay solutions for blood banks, clinical laboratories and transfusion centers. It produces plasma derived protein therapies for patients suffering with rare, genetic diseases and life-threatening infections. Grifols is headquartered in Sant Cugat del Valles, Barcelona, Spain.

Grifols SA Key Recent Developments

Apr 17,2017: Grifols Donates 140 Million International Units of Blood Clotting Factors to the World Federation of Hemophilia Humanitarian Aid Program

Apr 07,2017: Grifols participates at the 3rd International Conference on Research into Alpha-1 Antitrypsin Deficiency, and the 6th International Congress of Alpha-1 Patients

Feb 28,2017: Grifols' revenues exceed Euros 4,000 million, driven by +6.5% growth of the Bioscience Division

Nov 08,2016: Sales of the Bioscience Division grow by +6.5%, increasing Grifols' revenues to EUR 2,952 million

Oct 20,2016: The CLIA Lab at the Grifols Immunohematology Center Will Now Offer Both Serology and Molecular Tests

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Products

Products

Grifols SA, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Oryzon Genomics SA HemaCare Corp CSL Ltd Abeona Therapeutics Inc AB-Biotics SA

Table of Contents

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Grifols SA-Key Facts 6

Grifols SA-Key Employees 7

Grifols SA-Key Employee Biographies 8

Grifols SA-Major Products and Services 9

Grifols SA-Pharmaceutical Pipeline Products Data 10

Grifols SA, Pipeline Products by Therapy Area 10

Grifols SA, Pipeline Products by Development Phase 11

Grifols SA-History 12

Grifols SA-Company Statement 17

Grifols SA-Locations And Subsidiaries 18

Head Office 18

Other Locations & Subsidiaries 18

Section 2-Company Analysis 22

Grifols SA-Business Description 22

Grifols SA-Corporate Strategy 23

Grifols SA-SWOT Analysis 24

SWOT Analysis-Overview 24

Grifols SA-Strengths 24

Grifols SA-Weaknesses 25

Grifols SA-Opportunities 26

Grifols SA-Threats 27

Grifols SA-Key Competitors 28

Section 3-Company Financial Ratios 29

Financial Ratios-Capital Market Ratios 29

Financial Ratios-Annual Ratios 30

Performance Chart 33

Financial Performance 33

Financial Ratios-Interim Ratios 34

Financial Ratios-Ratio Charts 35

Section 4-Company's Lifesciences, Power Financial Deals and Alliances 36

Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 36

Grifols SA, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 37

Grifols SA, Recent Deals Summary 38

Section 5-Company's Recent Developments 39

Apr 17, 2017: Grifols Donates 140 Million International Units of Blood Clotting Factors to the World Federation of Hemophilia Humanitarian Aid Program 39

Apr 07, 2017: Grifols participates at the 3rd International Conference on Research into Alpha-1 Antitrypsin Deficiency, and the 6th International Congress of Alpha-1 Patients 40

Feb 28, 2017: Grifols' revenues exceed Euros 4,000 million, driven by +6.5% growth of the Bioscience Division 41

Nov 08, 2016: Sales of the Bioscience Division grow by +6.5%, increasing Grifols' revenues to EUR 2,952 million 49

Oct 20, 2016: The CLIA Lab at the Grifols Immunohematology Center Will Now Offer Both Serology and Molecular Tests 53

Jul 28, 2016: Sales of the Bioscience Division grow by +7.0%, increasing Grifols' revenues by +2.7% to EUR 1,952 million 54

Jul 05, 2016: Pedigri: the tool that increases the information transparency to the plasma-derived manufactured in Clayton 60

Jun 16, 2016: Grifols confirms that it has voluntarily signed the EFPIA Code of Conduct 61

May 19, 2016: Announcing the fourth Annual National Hemophilia Foundation Annual Meeting Pre-Conference Symposium 62

May 05, 2016: Grifols' revenues increase by +5.6% to Euros 959 million, driven by growth of +10.9% for the Bioscience Division 63

Section 6-Appendix 67

Methodology 67

Ratio Definitions 67

About GlobalData 71

Contact Us 71

Disclaimer 71


List of Figure

List of Figures

Grifols SA, Pipeline Products by Therapy Area 10

Grifols SA, Pipeline Products by Development Phase 11

Grifols SA, Performance Chart (2012-2016) 33

Grifols SA, Ratio Charts 35

Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 36

Grifols SA, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 37


List of Table

List of Tables

Grifols SA, Key Facts 6

Grifols SA, Key Employees 7

Grifols SA, Key Employee Biographies 8

Grifols SA, Major Products and Services 9

Grifols SA, Number of Pipeline Products by Therapy Area 10

Grifols SA, Number of Pipeline Products by Development Stage 11

Grifols SA, History 12

Grifols SA, Other Locations 18

Grifols SA, Subsidiaries 18

Grifols SA, Key Competitors 28

Grifols SA, Ratios based on current share price 29

Grifols SA, Annual Ratios 30

Grifols SA, Annual Ratios (Cont...1) 31

Grifols SA, Annual Ratios (Cont...2) 32

Grifols SA, Interim Ratios 34

Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 36

Grifols SA, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 37

Grifols SA, Recent Deals Summary 38

Currency Codes 67

Capital Market Ratios 67

Equity Ratios 68

Profitability Ratios 68

Cost Ratios 69

Liquidity Ratios 69

Leverage Ratios 70

Efficiency Ratios 70

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022